Atossa Therapeutics (Atossa Therapeutics) Price-to-Owner-Earnings : (As of May. 16, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Atossa Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-16), Atossa Therapeutics's share price is $1.62. Atossa Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.

The historical rank and industry rank for Atossa Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

ATOS's Price-to-Owner-Earnings is not ranked ^*
in the Biotechnology industry.
Industry Median: 34.045
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-16), Atossa Therapeutics's share price is $1.62. Atossa Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.24. Therefore, Atossa Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-16), Atossa Therapeutics's share price is $1.62. Atossa Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.22. Therefore, Atossa Therapeutics's PE Ratio without NRI for today is At Loss.

Atossa Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Atossa Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Price-to-Owner-Earnings Chart

Atossa Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Owner-Earnings

Get a 7-Day Free Trial

Atossa Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Owner-Earnings	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Atossa Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Atossa Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atossa Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's Price-to-Owner-Earnings falls into.

Atossa Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Atossa Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	1.62	/	-0.20
	=

Atossa Therapeutics (NAS:ATOS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

Atossa Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics (Atossa Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (NAS:ATOS) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

ATOS:Mexico YAG2:Germany

Address

107 Spring Street, Seattle, WA, USA, 98104

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Executives

Gregory L Weaver	director	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Heather Rees	officer: SVP, Finance and Accounting	C/O ATOSSA THERAPEUTICS, INC., 107 SPRING STREET, SEATTLE WA 98104
Kyle Guse	officer: CFO & General Counsel	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98102
H. Lawrence Remmel	director	C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
Shu-chih Chen	director, 10 percent owner, officer: Chief Scientific Officer	C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112
Steven C Quay	director, 10 percent owner, officer: CEO	22026 20TH AVENUE S E, SUITE 102, BOTHELL WA 98021
Scott Youmans	officer: Chief Operating Officer	ATOSSA GENETICS INC., 2345 EASTLAKE AVE. E, SUITE 201, SEATTLE WA 98102
John E Sawyer	officer: See Remarks	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98021
Christopher S. Destro	officer: SVP, Sales and Marketing	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Peter J. Carbonaro	officer: Sr. Vice President, Operations	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Ben R Chen	officer: Sr. VP of Glob. Reg. Affairs	1616 EASTLAKE AVENUE EAST, SUITE 510, SEATTLE WA 98102
Richard I Steinhart	director	125 ELM STREET, NEW CANAAN CT 06840
Alexander D Cross	director	C/O LIGAND PHARMACEUTICALS INC.,, 10275 SCIENCE CENTER DR., SAN DIEGO CA 92121
Stephen J Galli	director	C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
John Barnhart	director	C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112